leadf
logo-loader
viewTRACON Pharmaceuticals

TRACON Pharmaceuticals says first patient dosed in ENVASARC registration trial to treat soft-tissue sarcoma cancer

The pivotal study, which will involve 25 top cancer centers in the US, will assess the potential of envafolimab and in combination with monoclonal antibody Yervoy, which is used to treat late-stage metastatic melanoma

TRACON Pharmaceuticals - TRACON Pharmaceuticals Inc dosing of the first patient in the ENVASARC registration trial to treat soft-tissue sarcoma cancer
Planned total enrollment is 160 patients — with 80 patients enrolled into cohort A of treatment with envafolimab and 80 patients enrolled in cohort B of treatment with envafolimab and Yervoy

TRACON Pharmaceuticals (NASDAQ:TCON), which develops a clinical-stage pipeline of cancer therapies, announced Thursday the dosing of the first patient in the ENVASARC registration trial to treat soft-tissue sarcoma cancer. 

The pivotal study, which will involve 25 top cancer centers in the US, will assess the potential of envafolimab as a single agent and in combination with monoclonal antibody Yervoy (ipilimumab), which is used to treat late-stage, metastatic melanoma. 

“We are pleased to initiate dosing in the ENVASARC registration trial of envafolimab in sarcoma,” said Dr Sant Chawla, director of the Sarcoma Oncology Center in Santa Monica. “Immunotherapy has radically changed the treatment paradigm for a number of cancers, and we believe envafolimab has the potential to do the same for sarcoma patients who have few treatment options.”

READ: TRACON Pharmaceuticals strengthens its cash position in 3Q to fund operations into 2022

The trial will be a multi-center, open-label, randomized, non-comparative, parallel cohort study. Planned total enrollment is 160 patients -- with 80 patients enrolled into cohort A of treatment with envafolimab and 80 patients enrolled in cohort B of treatment with envafolimab and Yervoy.

San Diego-based TRACON said eligible patients will have undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) and received one or two prior cancer therapies, but no prior immune checkpoint inhibitor therapy.

“Dosing the first patient in the ENVASARC registration trial within one year of executing the license to envafolimab fulfills our 2020 expectations for what has been a productive year of clinical development and regulatory interactions for our lead product candidate,” said Dr Charles Theuer, CEO of TRACON, in a statement.

“We look forward to the availability of interim top-line data from this important study, which we expect in mid-2021.”

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: TRACON Pharmaceuticals

Price: 9.17 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $133.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

TRACON's partners submit new drug application for approval of envafolimab to...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a new drug application for the approval of envafolimab in the indication of MSI-H/dMMR cancer to the National Medical Products Administration in...

on 11/19/2020

2 min read